Analysis using the Cancer Therapeutics Response Portal (CTRP) database revealed a negative correlation between ELFN1 levels and the IC50 values of multiple compounds, including GSK-J4, PF-3758309, omacetaxine mepesuccinate, brivanib, BRD-K35604418, oligomycin A, axitinib, and valdecoxib (Supplementary Figure S10A). The gene discussed is ELFN1; the disease is cancer.